Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3075% below fair value
$8.07−0.17 (-2.00%)
Close on Nov 13, 2026Market cap $46.69MP/E –Yield –
Xilio Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Xilio Therapeutics
Xilio Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?